TABLE 2.

Antimicrobial susceptibilities of clinical strains 2, 3, and 4 of P. luminescens isolated from Australian patients

Strain no.	Zone size (mm) fora:
	AMC	AMP	CAZ	CRO	CEF	CHL	CIP	GEN	IPM	KAN	NAL	PEN	TET	TIC	TIM	TOB	TMP	SXT
2	20	<6	31	31	<6	28	32	23	25	28	33	<6	28	32	32	22	24	28
3	20	<6	31	31	<6	28	32	24	25	26	32	<6	27	32	32	22	23	28
4	19	<6	31	31	<6	28	32	21	24	26	32	<6	26	32	32	22	24	28
Mean	19.6		31	31		28	32	22.7	24.7	26.7	32.3		27	32	32	22	23.7	28
SD	0.6		0	0		0	0	1.5	0.6	1.6	0.6		1	0	0	0	0.6	0
CDC meanb		10			0	39		26		32	36	6	33
% Susceptible	100	0	100	100	0	100	100	100	100	100	100	0	100	100	100	100	100	100

^aAMC, amoxicillin-clavulanic acid (20/10 μg); AMP, ampicillin (10 μg); CAZ, ceftazidime (30 μg); CRO, ceftriaxone (30 μg); CEF, cephalothin (30 μg); CHL, chloramphenicol (30 μg); CIP, ciprofloxacin (5 μg); GEN, gentamicin (10 μg); IPM, imipenem (10 μg); KAN, kanamycin (30 μg); NAL, nalidixic acid (30 μg); PEN, penicillin (10 U); TET, tetracycline (30 μg); TIC, ticarcillin (75 μg); TIM, ticarcillin-clavulanic acid (75/10 μg); TOB, tobramycin (10 μg); TMP, trimethoprim (5 μg); SXT, trimethoprim-sulfamethoxazole (1.25/23.75 μg). 

^bPreviously published zone sizes for U.S. clinical strains of P. luminescens.